Skip to main content
Fr Donate
  1. Home
  2. Research
  3. For researchers
  4. Current funding opportunities
  5. Research grants for uterine carcinosarcoma and other aggressive uterine cancers

Research grants for uterine carcinosarcoma and other aggressive uterine cancers

  1. Home
  2. Research
  3. For researchers
  4. Current funding opportunities
  5. Research grants for uterine carcinosarcoma and other aggressive uterine cancers

Highlights of the program

Uterine cancer is the most common cancer of the female reproductive system and the fourth most common cancer diagnosed in females in Canada (Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019). While almost all uterine cancers are endometrial carcinoma (beginning in the lining of the uterus), about 2-5% are uterine sarcomas, beginning in the muscle or connective tissue of the uterus.

The application guide can be found on the EGrAMS documentation for applicants page.

Please see the eligibility and requirements section prior to creating an application.

Full applications due:
April 14, 2020
Results announcement:
August 2020
Anticipated start date:
September 1, 2020

Program description

The Canadian Cancer Society (CCS) is issuing a special call for grant applications focused on rare and aggressive uterine cancers, with an emphasis on uterine carcinosarcoma in particular. As a result of a generous donation, there is funding available to support one meritorious application that will impact our understanding of uterine carcinosarcoma and other aggressive uterine cancers, particularly as it relates to the prevention, early detection, diagnosis, and/or treatment of these hard-to-treat cancers.

Eligible types of uterine cancer include:

  • Uterine carcinosarcoma
  • Serous carcinoma
  • Uterine leiomyosarcoma
  • Uterine clear cell carcinoma
  • Endometrial stromal sarcoma (high-grade)
  • Undifferentiated sarcomas

Applications that build new collaborations and capacity in uterine carcinosarcoma and other aggressive uterine cancer research are encouraged.

CCS is committed to equity, diversity and inclusivity and strives to support all genders and backgrounds in its research programs. We welcome eligible applicants of diverse backgrounds to apply for our funding opportunities.

Funds available

It is anticipated that 1 grant will be awarded in this competition.

The funding envelope will support a budget of up to $180,000 over 2 years (maximum of $90,000 per year). This grant is renewable for an additional 2 years of funding pending review.

Funding will be provided to support the direct costs of research, including supplies, eligible salaries, and equipment associated with the proposed work. Equipment requests cannot exceed 15% of the requested budget. Indirect costs are not eligible.

Total budget
up to $180,000
One-year period

up to $90,000 

Renewable

Yes

Equipment
15% budget

A peer review committee will be assembled to review the full applications. The peer review committee will consist of scientists with expertise relevant to the submitted applications.

The proposal will contain no more than 5 pages of single-spaced text and 2 pages of figures/tables/charts and associated legends. Specific guidelines for the online application are available here.

When preparing the full application, the following is required:

  1. a “public” (non-scientific) summary
  2. a scientific abstract
  3. a relevance statement explicitly demonstrating how the project is relevant to uterine carcinosarcoma and/or other aggressive uterine cancers (see list above).
  4. a detailed scientific proposal clearly stating the aims of the project including any previous work done in the area, experimental design, methods and analysis.
    Investigators must provide a convincing rationale for the hypothesis. Details of the investigator(s) including which member(s) of the research team will be responsible for which aspect of the project and a rationale for their inclusion in the project are required, and a description of the research environment where the work will take place.
    • Investigators must provide a convincing rationale for the hypothesis. Details of the investigator(s) including which member(s) of the research team will be responsible for which aspect of the project and a rationale for their inclusion in the project are required, and a description of the research environment where the work will take place.
  5. a budget justification related to the supplies, equipment and personnel associated with the research project. This must include the number of personnel required to complete the work and a description of their experience and/or education level and their commitment to the project.

The review criteria for the full application will include, but not necessarily be restricted to, four assessment categories: Research Strategy, Investigator(s), Environment, and Relevance.

Research strategy

  • scientific merit and convincing rationale that considers critical review and analysis of preliminary data and/or published literature, as appropriate
  • identification of potential problems and how they will be addressed, including alternative approaches
  • appropriateness of the term and amount of support requested

Investigator(s)

  • qualifications and appropriate expertise of the investigator(s)

Environment

  • quality of the research environment in which the work will take place

Relevance

  • potential impact on uterine carcinosarcoma and/or other aggressive uterine cancers, particularly as it related to prevention, detection, diagnosis and/or treatment of these cancers

It is understood that applications may also be made to other agencies to provide support for grants/programs similar to those submitted to the Canadian Cancer Society. For this competition, duplicate applications submitted to other agencies will be accepted, but budgetary overlap will not be permitted at the funding stage.

Applicants are reminded to review the eligibility and requirements section for details on scientific and financial reporting, funder acknowledgement, Canadian Cancer Society policies on open access and tobacco related funding.

Last modified on: February 16, 2021